FDA Corrects Guidance Document on COVID-19-Related Symptoms in Clinical Trials

Summary

The US Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 22, 2024, due to an error in the docket number of a final guidance document related to assessing COVID-19-related symptoms in outpatient adult and adolescent subjects participating in clinical trials of COVID-19 prevention or treatment drugs and biological products.